Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 8/20 | 0.43 |
| ▸ | CCNH | P51946 | 8/20 | 0.43 |
| ▸ | MNAT1 | P51948 | 8/20 | 0.43 |
| ▸ | CCNK | O75909 | 5/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.43 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559182 | 0.98 | CDK2 (0.50) | CDK2CCNE1MAPK1ABL1CDK7 | |
| SCHEMBL559618 | 0.97 | CDK2 (0.49) | CDK2CCNE1MAPK1ABL1CDK7 | |
| SCHEMBL2259965 | 0.92 | CCNE1 (0.46) | CDK2CCNE1MAPK1ABL1CDK7 | |
| SCHEMBL559799 | 0.92 | CCNE1 (0.46) | CDK2CCNE1MAPK1ABL1CDK7 | |
| SCHEMBL560024 | 0.83 | NPC1 (0.46) | MAPK1ABL1CNR2 | |
| SCHEMBL559996 | 0.82 | CDK2 (0.50) | CDK2CCNE1MAPK1CDK7CCNH | |
| SCHEMBL559713 | 0.81 | MAPK1 (0.55) | CDK2CCNE1MAPK1 | |
| SCHEMBL559349 | 0.80 | CDK2 (0.50) | CDK2CCNE1MAPK1CDK7CCNH | |
| SCHEMBL559392 | 0.80 | MAPK1 (0.53) | CDK2CCNE1MAPK1CDK7CCNH | |
| SCHEMBL559836 | 0.80 | MAPK1 (0.53) | CDK2CCNE1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998978-B2 | Substituted 2-amino-fused heterocyclic compounds | PFIZER INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | CDK2 125/4885CCNE1 523/4885MAPK1 1/4885 |
| US-20100056506-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | CDK2 125/4885CCNE1 523/4885MAPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.